

Anti-Cancer Drugs 2006

Key Word Index to Volume 17

- 2-methoxyestradiol, 977
 25-anhydrocymigenol-3-O- β -D-xylopyranoside, 545
 4-week regimen, 2315-Aza-2'-deoxycytidine, 251
 5-fluoro-5'-deoxyuridine, 807
 5-fluorodeoxyuridine monophosphate, 439
 5-fluorouracil, 89, 225, 345, 377, 393, 439, 445, 463, 985, 1067, 1087
 9-aminocamptothecin, 571
 9-hydroxystearic acid, 521
 A431 cells, 479
 abarelix, 1075
 ABCG2, 239
 actinic keratosis, 1087
 acute myeloid leukemia, 385, 1081
 AD 198, 495
 adamantylamine, 201
 adenovirus E4orf4, 527
 adjuvant chemotherapy, 103, 705
 adjuvant hormonal therapy, 245
 adjuvant hormone therapy, 719
 adriamycin, 81
 advanced gastric cancer, 231
 AG879, 929
 AKT, 261
 Akt, 455, 733
 alanine aminotransferase, 709
 all-*trans* retinoic acid, 559, 1127
 amifostine, 133
 amplified in breast cancer 1, 733
 anastrozole, 719
 aneugenic effects, 289
 angiogenesis, 13, 479, 839, 961
 angiogenesis inhibitors, 997
 angiosarcoma, 997
 anthracycline, 337
 anthracycline retreatment, 587
 anti-angiogenesis, 269
 anti-angiogenic therapy, 113
 anti-cancer agent, 297
 anti-cancer drugs, 333, 905
 anti-EGFR, 365
 anti-leukemic activity, 511
 anti-proliferation, 545
 anti-tumor activity, 201, 269, 539
 anti-tumor agents, 41
 antibiotics, 881
 antibodies, 815
 anticancer drug combination, 807
 anticancer drug, 825
 anticancer molecules, 1017
 antileukemia, 641
 antisense, 181, 1031
 antitumor immunity, 1045
 APEX, 1045
 apoptosis, 33, 155, 181, 269, 279, 307, 315, 325, 471, 495, 527, 545, 621, 641, 763, 797, 825, 943, 949, 1031, 1151, 1163
 aromatase inhibition, 999
 arterial hypertension, 133
 aspartate aminotransferase, 709
 aspermatogenesis, 815
 aspirin, 423
 ATP-binding cassette transporters, 239
 ATP-tumor chemosensitivity assay, 649
 atrial fibrillation, 359
 autoimmune diseases, 133
 azo-procarbazine, 75
 B-steroidal lactams, 511
 Bak, 471
 bastadin 6, 269
 Bax, 471, 797
 BBR 3464, 697
 Bcl-2, 495, 797, 1141
 bevacizumab (Avastin), 1227
 bicalutamide, 245
 biomarkers, 1179
 bioreductive, 21
 biweekly regimen, 985
 bladder cancer, 705
 bolus, 89, 439
 bortezomib, 455
 brain cancer, 1003
 breast cancer, 33, 337, 455, 709, 719, 1067, 1089, 1201
 breast cancer and prognosis, 961
 breast cancer cells, 173
 breast cancer resistance protein, 239
 busulfan, 657, 1095
 β -catenin, 753
 c-Abl, 609
 c-myc, 181
 caffeic acid phenethyl ester, 753
 caffeine, 1171
 Caki-1, 333
 calcium, 207
 cancer, 13, 25, 123, 143, 279, 487, 725, 815, 1017
 cancer therapeutics, 1099
 cancer therapy, 943
 cantharidin analogues, 905
 capecitabine, 231, 921, 1087
 carboplatin, 289
 carcinoid, 139
 cardiac toxicity, 359
 cardiolipin-gemcitabine conjugate, 53
 cardiotoxicity, 587
 caspase-3, 307, 641
 caspases, 315, 1151
 cathepsin B, 1119
 Cdc6, 307
 celecoxib, 609
 cell, 815
 cell cycle, 545, 825, 1171
 cell cycle arrest, 173
 cell cycle block, 825
 cell cycle progression, 521
 cell death, 663
 cell growth, 1163
 cell motility, 13
 cell proliferation, 325
 cell survival, 1171
 cervical cancer, 715
 cetuximab, 855
 cetuximab (Erbix), 1227
 chelidonium alkaloids, 1025
 chemoprevention, 471, 663
 chemoradiation, 95, 969
 chemoresistance, 1045
 chemosensitivity, 649, 913, 1045
 chemotherapy, 123, 225, 411, 571, 881, 993, 1003, 1045
 chemotherapy toxicity, 103
 childhood, 385, 1081
 children, 859, 1095, 1231
 Chk1 protein, 1171
 chlorambucil, 511
 cholangiocarcinoma, 783
 chromogranin A, 849
 chronic myeloid leukemia, 631
cis-platinum, 733
 cisplatin, 81, 207, 289, 333, 553, 565, 705, 1031, 1211
 clastogenic damage, 289
 coculture, 771
 colon cancer, 103, 521, 943
 colorectal cancer, 609, 753, 855, 865, 1227
 colorectal carcinogenesis, 471
 colorectal carcinoma, 985
 combi-molecule, 165
 combination, 377
 combustion method, 63
 Comet assay, 155

- complication, 423
 continuous, 439
 coronary heart disease, 133
 correlations, 41
 Cox-2, 365
 CPT-11, 89
 CRT, 365
 curcumin, 279
 cyclodextrin, 33
 cyclopentenone, 1017
 cyclophosphamide, 1025
 cycloplatan, 289
 cytarabine, 597
 cytogenetic effects, 289
 cytosine arabinoside, 597
 cytotoxic drug sensitivity, 503
 cytotoxicity, 41, 527, 825, 905

 D-steroidal lactams, 511
 DEAD/H box helicase 21, 733
 death-associated protein kinase, 251
 delayed emesis, 217
 derivative, 279
 dermatofibrosarcoma protuberans, 1223
 dexamethasone, 207
 diabetes, 133
 diesterified bisphosphonate, 479
 differentiation, 521, 1127
 dihydroartemisinin, 839
 dihydropyrimidine dehydrogenase, 1087
 diphosphonates, 621
 DNA mismatch repair, 315
 DNA replication, 307
 DNA strand break, 155
 docetaxel, 63, 225, 401, 807, 993
 doxorubicin, 385, 1025
 drug combinations, 631
 drug design, 1017
 drug discovery, 1017
 drug interaction, 445
 drug resistance, 315, 621, 1171
 DU-145, 1163
 dual tyrosine kinase inhibitor, 921
 efficacy, 1, 53
 EGFR tyrosine kinase inhibitor, 401
 embryonic, 859
 epidermal growth factor, 527
 epidermal growth factor receptor, 95, 401, 855, 921, 1227
 epidermal growth factor receptor inhibitor, 165
 epinephrine, 1211
 Epstein-Barr virus, 685
 equilibrium dialysis, 977
 erlotinib, 95, 783, 807
 esophageal cancer, 95
 esophageal neoplasm, 503
 estramustine, 113
 etoposide, 155, 1025, 1081
Eucheuma serra agglutinin, 943
 Ewing tumor, 657, 1025
 extracellular signal-regulated kinase 1/2, 553, 839
 extracellular signal-regulated protein kinase, 429

 farnesylthiosalicylic acid, 33
 Fas, 1141
 FasL, 1141
 fatty liver, 709
 febrile neutropenia, 881
 first-line therapy, 565
 flare phenomenon, 993
 flavanone, 641
 fluorescence *in situ* hybridization, 289
 fluorinated RNA, 439
 fluorometric microculture cytotoxicity assay, 631
 fluorouracil, 1201
 food, 353
 fusion protein, 527

 γ -glutamyltranspeptidase, 1127
 G₂/M checkpoint, 315
 gastrectomy, 393
 gastric cancer, 231, 581
 gefitinib, 401, 423, 783
 gemcitabine resistance, 53
 gemcitabine, 81, 107, 359, 565, 685, 705, 859, 1185
 genotoxicity, 289
 germ cell tumor, 1057
 gimeracil, 393
 glassy cell carcinoma, 715
 glioblastoma, 189
 glioblastoma multiforme, 969
 glioma, 733, 1003
 glioma cells, 663
 glitazones, 325
 Glivec, 649
 glucose-6-phosphate dehydrogenase, 133
 glutathione, 21, 41, 1127
 granulocyte colony-stimulating factor, 345, 881
 Grb2, 13
 growth factor receptor-bound 2, 13

 Hdm2, 609
 head and neck cancer, 365, 377
 hepatocellular carcinoma, 261
 hepatocyte growth factor, 733
 heptaplatin (SKI-2053R), 377
 high dose, 597
 high-dose chemotherapy, 657, 1057
 high-performance liquid chromatography, 673
 hippocampal organotypic cultures, 663
 histoculture drug response assay, 553
 histologic response, 411
 histone deacetylase, 1141
 Hodgkin's disease, 685
 hormone antagonists, 1075
 hormone receptor-positive, 999
 HT29, 463
 human, 75
 human colon cancer, 553
 human hepatoma cells SMMC-7721, 797
 human prostate cancer, 1163
 HuR, 429
 hydrochlorothiazide, 207
 hydroxymethylglutaryl-CoA reductase inhibitors, 621
 hypoxia, 21, 839

 idarubicin, 69
 idarubicinol, 69
 imatinib, 649
 imatinib mesylate, 631, 1223
 imexon, 1179
 immunogenicity, 815
 immunosuppression, 815
 immunotherapy, 1
 implanted mice hepatoma, 545
in vivo, 201
in vitro drug sensitivity, 631
 inhibitor of apoptosis protein, 261
 inhibitor, 21
 interaction, 1185
 interleukin-2, 1
 interstitial fluid pressure, 949
 intraperitoneal chemotherapy, 1211
 intravenous, 89, 1095
 invasion, 1099
 irinotecan, 89, 985
 isolated limb perfusion, 949
 isothiocyanate, 297

 K101, 553
 Ki-67, 1201
 kinamycin, 825
 kinase inhibitor, 1003

 LA-12, 201
 laminin receptor, 429
 lectin, 943
 leucovorin, 89
 leukemia, 487
 leukocyte infiltration, 949
 Lewis lung carcinoma, 195

- lichen metabolites, 1163
- lidamycin, 173
- linitis plastica, 581
- lipoplatin, 315
- liposarcoma, 891
- liposomal doxorubicin, 587
- liquid scintillation counting, 63
- liver dysfunction, 1219
- liver sonography, 709
- locally advanced, 245
- lung adenocarcinoma cells, 771
- lung fibroblasts, 771
- lung metastasis, 195
- lymphotoxins, 1045

- macrophages, 1119
- malignant melanoma, 325
- mammalian target of rapamycin, 487
- mantle cell lymphoma, 763
- matrix metalloproteinase, 189
- Mb Down, 385, 1081
- Mdm2, 725
- mdr1* gene, 1044
- medullary thyroid cancer, 139, 849
- melanoma, 815, 1031, 1151
- melanoma inhibitor of apoptosis protein, 1031
- MEN 4901/T-0128, 1119
- mesenchymal, 859
- mesothelioma, 1231
- metabolism, 463
- metalloproteinase-9, 429
- metastasis, 13, 429, 1099
- metastatic breast cancer, 345, 565, 999, 1193
- metastatic disease, 1223
- methotrexate, 411, 1171
- methylation, 251
- metopimazine, 217
- metronomic chemotherapy, 113, 961
- mice, 815
- micro RNA, 1099
- micronucleus test, 289
- mitochondria, 155, 495, 1017, 1151
- mitochondrial depolarization, 1141
- mTOR, 487
- mTOR inhibitor, 487
- mTOR kinase, 487
- multidrug resistance, 1044
- multidrug resistance modulators, 239
- multiple myeloma, 621, 839
- muscular sarcoma, 929

- N,N',N''*-triethylenethiophosphoramidate, 1025
- N*-acetylcysteine conjugate, 297
- N*-methylformamide, 521
- nasopharyngeal carcinoma, 251

- natural killer cells, 1045
- natural product, 25
- necrosis, 1163
- nelfinavir, 891
- neoadjuvant chemotherapy, 715
- neoadjuvant treatment, 1089
- neoplasm, 1171
- nephrotoxicity, 207, 673
- nerve growth factor, 929
- neuroblastoma, 657
- neuroendocrine tumor, 849
- neutralizing antibodies, 929
- neutropenia, 865
- new drugs, 869
- non-small-cell lung cancer, 401
- noncoding RNA, 1099
- norcantharidin, 307
- NPI-2358, 25
- nuclear factor- κ B, 733
- nucleoside transporter, 53
- nude mice, 559
- NVP-AEE788, 783

- octahedral Pt(IV) complex, 553
- octreotide, 601
- once-daily, 1095
- ondansetron, 207, 217
- oral chemotherapy, 1089
- organogold compounds, 539
- osteosarcoma, 411
- ovarian ablation, 999
- ovarian cancer, 1044, 1211
- ovarian cancer cell lines, 913
- oxaliplatin, 103, 337, 417, 445, 865, 985, 1067, 1185

- P-glycoprotein, 195
- P-selectin, 423
- p21^{WAF-1}, 553
- p53, 173, 553, 609, 725
- p75, 929
- paclitaxel, 195, 225, 377, 1044, 1219
- paclitaxel and carboplatin therapy, 715
- pancreas cancer, 1045
- pancreatic cancer, 107
- pathological complete remission, 1201
- pemetrexed, 1231
- perioperative chemotherapy, 1201
- peripheral blood stem cell transplantation, 1057
- peripheral neuropathy, 1087
- peritoneal carcinomatosis, 1211
- peritoneal neoplasms, 1231
- peroxisome proliferator-activated receptor γ , 325

- peroxisome proliferator-activated receptor, 763
- phagocytosis, 1119
- pharmacoeconomics, 719
- pharmacokinetics, 75, 165, 353, 385, 393, 1081, 1179, 1185, 1219
- phase I, 81, 417, 571
- phase I trials, 113
- phase II, 565
- Phenoxodiol, 1151
- phosphorothioated, 143
- platinum complexes, 201
- platinum drugs, 289
- polycystic kidney disease 1, 733
- polyneuropathy, 1087
- polyphenols, 471
- posttransplant lymphoproliferative disease, 685
- PPAR- γ , 763
- pre-treated, 337
- premenopause, 999
- preoperative chemotherapy, 1201
- procarbazine, 75
- prognostic factors, 1193
- proliferation, 1127
- prophylaxis, 881
- prostate cancer, 245, 429, 807, 993, 1075
- proteasome inhibitor, 261, 455
- protein binding, 977
- protein kinase C, 495
- protein phosphatase 2A, 905
- protein targets, 1017
- PTEN, 455

- quantitative real-time reverse-transcriptase polymerase chain reaction, 1044
- quercetin, 663

- Rad9 homolog A (*Schizosaccharomyces pombe*) protein, 1171
- radiation recall phenomenon, 107
- radiation, 107
- radiosensitization, 95
- radiotherapy, 245, 969
- raf-1, 849
- Ras, 33
- Ras/Raf signaling, 139
- rash, 1227
- rat, 69
- reactive oxygen species, 155, 609
- recombinant interleukin-2, 195
- recurrent gastric cancer, 231
- relapsed, 697
- renal cell cancer, 333
- resistance, 41, 463

- review, 881
- rhabdomyosarcoma, 1127
- ribonuclease, 815
- rituximab, 685
- RNA interference, 1099

- S-1, 393
- saliva, 597
- satraplatin, 201
- scatter factor, 733
- schedule-dependence, 445
- second line, 697
- second-line therapy, 401
- secreted protein acidic and rich in cysteine, 189
- selective targeting, 527
- sensitivity, 181
- sensory neuropathy, 103
- serum-free culture conditions, 913
- severe enterocolitis, 865
- simvastatin, 621
- small cell lung cancer, 697
- small molecules, 123, 725
- sodium butyrate, 559
- solid tumors other than melanoma and renal carcinoma, 1
- solid tumors, 601, 859, 881, 1185
- SOM230, 601
- somatostatin, 601
- Src, 123
- Stat3, 1045
- state-of-the-art, 365
- steroidal esters, 511
- sterol regulatory element binding protein-1, 891
- stomach cancer, 225
- structure-activity relationships, 239, 511
- SU11248, 353
- SU12662, 353
- sulfur-containing bionucleophiles, 673

- sunitinib malate, 353
- survival, 993

- T-cell factor, 753
- tafluposide, 155
- tamoxifen, 709, 719
- targeted therapy, 869, 1003
- taxane, 337
- telomerase activity, 503
- temozolomide, 113, 969
- therapeutic, 143
- therapy, 725
- thiazolidinediones, 325
- thiols, 21, 1179
- thioredoxin reductase, 539
- thioredoxin, 539
- thymidine kinase, 463
- thymidylate synthase, 463
- thymidylate synthase activity, 439
- thyroid cancer, 559, 849
- thyroid carcinoma, 869
- titanocene, 333
- TKI, 365
- tomudex, 865
- topoisomerase, 155
- topoisomerase I, 825
- topoisomerase II, 825
- toxicity, 53
- traditional Chinese medicine, 905
- traditional Chinese medicine-platinum compounds, 673
- TRAIL, 261
- trastuzumab, 455
- treatment, 487
- treosulfan, 657
- triazene, 165
- triplet regimen, 985
- tritium, 63
- trofosfamide, 997
- TS-1, 581
- tubulin-depolymerizing agent, 25

- tumor growth, 479
- tumor necrosis factor- α , 949
- tumour cells, 1171
- tumour targeting, 1119
- TxB₂, 423
- tyrosine kinase, 21
- tyrosine kinase inhibitor, 783
- tyrosine kinase receptor A, 929

- U373MG, 733
- UFT, 417
- Ukrain, 189, 1025
- urinary bladder cancer, 297
- urokinase plasminogen activator, 1099
- urokinase plasminogen activator receptor, 1099

- validation, 63
- vascular damage, 949
- vascular effects, 69
- vascular endothelial growth factor, 839, 1045, 1227
- vascular-disrupting agent, 25
- vinblastine, 181
- vinorelbine, 337, 1067

- weekly chemotherapy, 1193
- weekly paclitaxel, 345
- wheat, 815
- WNT signaling, 753
- wogonin, 797

- xanthine oxidase, 609
- xenograft model, 849
- xenografts, 143, 201, 1179
- xeroderma pigmentosum, 133
- XRT, 365

- ZM336372, 139
- zoledronic acid, 621